Sector News

Matchmaking for Shire and AbbVie already? Try Allergan (of course) and Pfizer

October 16, 2014
Life sciences
Now that AbbVie has said it wants to dump Shire, we could soon have two companies back on the market–and both could prove popular as the dust settles. In fact, as Bloomberg reports, AbbVie could make a decent second choice to AstraZeneca if Pfizer so chooses.
 
And do we have to mention the fact that Allergan might be happy to step in where AbbVie is stepping out? A Shire-Allergan merger has been chatted about for some time, after all. And Allergan would dearly love to make a deal to help defend itself against Valeant Pharmaceuticals, which is determined to come in and take over.
 
Allergan reportedly has lost its chance to snap up Salix, which is now in talks with Actavis instead. With Shire back in play, it may be Allergan’s best chance to fix its Valeant problem. Provided all the legal snarls with Valeant and its buyout partner Bill Ackman could be ironed out, of course.
 
The idea of Pfizer turning away from AstraZeneca to nab AbbVie isn’t new, either. But with the Obama administration’s new tax inversion limits, the Pfizer-AZ combo looks less favorable, just as AbbVie’s Shire buyout does. So, if Pfizer CEO Ian Read doesn’t fancy a new fight in the U.K. next month–and can’t persuade AZ to come quietly–then it may want to turn toward Chicago instead.
 
Meanwhile, Shire could turn around and become a buyer again, too. If Actavis doesn’t nab Salix, then Shire might step in. Both have gastrointestinal meds, offering some synergies. Jefferies analyst David Steinberg reminds Bloomberg that Shire has been on an acquisition trail, with one smallish deal after another. It could continue to be a “serial consolidator” in the orphan drug business.
 
Of course, AbbVie may just be trying to squeeze Shire on price, so the deal might find new life. As analyst David Amsellem tells Bloomberg, “The transaction is very much alive,” Amsellem said. “It’s just a question of price, if it’s not an inversion.”
 
By Tracy Staton
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach